# BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

> **NCT00656136** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 585 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** placebo
- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT00656136
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 585 (ACTUAL)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656136, "BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00656136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*